• In August 2026, Schrödinger, Inc. reported that second-quarter 2026 revenue rose to US$58.89 million and swung from a prior-year loss to net income of US$5.98 million, while also filing a US$46.95 million shelf registration for 3,000,000 common shares related to its employee stock ownership plan.
• On the same day, Bristol Myers Squibb announced it would deploy Schrödinger’s agentic AI co-scientist Bunsen across its research organization, expanding a long-running collaboration and spotlighting real-world integration of Schrödinger’s physics-based and AI discovery tools in large-scale pharmaceutical workflows.
• Next, we’ll examine how this move to embed Bunsen within Bristol Myers Squibb’s research organization influences Schrödinger’s longer-term investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Schrödinger Investment Narrative Recap

To be a shareholder in Schrödinger, you need to believe its physics based and AI powered discovery tools can become deeply embedded in large pharma workflows and eventually support more consistent profitability. The Q2 2026 swing to US$5.98 million in net income and the new Bristol Myers Squibb Bunsen deployment both speak directly to that thesis. The largest near term catalyst remains broader enterprise adoption of Bunsen, while the key risk is still margin pressure from heavy R&D and platform investment.

Among the recent announcements, the Bristol Myers Squibb agreement is the most directly relevant. It shows Bunsen moving from early access into a real, scaled deployment inside a top tier pharma, alongside Schrödinger’s existing computational platform and RetroSynth. For investors focused on catalysts, this kind of embedded use case may matter more than the ESOP related shelf filing, because it ties the long term software growth story to concrete, high value customer workflows.

Yet despite the excitement around Bunsen, investors should also be aware that heavy ongoing R&D and margin pressure could still...

Schrödinger's narrative projects $349.6 million revenue and $23.4 million earnings by 2029. This requires 11.1% yearly revenue growth and a $126.9 million earnings increase from -$103.5 million today.

Uncover how Schrödinger's forecasts yield a $20.88 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming only 8.7% annual revenue growth and ongoing losses, highlighting how views can differ and may shift after Bunsen’s Bristol rollout.

Explore 4 other fair value estimates on Schrödinger - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Schrödinger research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Schrödinger research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Schrödinger's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.